244 related articles for article (PubMed ID: 26287531)
1. Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.
Wu CY; Lin YW; Kuo CH; Liu WH; Tai HF; Pan CH; Chen YT; Hsiao PW; Chan CH; Chang CC; Liu CC; Chow YH; Chen JR
PLoS One; 2015; 10(8):e0136420. PubMed ID: 26287531
[TBL] [Abstract][Full Text] [Related]
2. Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.
Imura A; Sudaka Y; Takashino A; Tamura K; Kobayashi K; Nagata N; Nishimura H; Mizuta K; Koike S
J Virol; 2020 Feb; 94(6):. PubMed ID: 31896594
[TBL] [Abstract][Full Text] [Related]
3. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71.
Lin YW; Yu SL; Shao HY; Lin HY; Liu CC; Hsiao KN; Chitra E; Tsou YL; Chang HW; Sia C; Chong P; Chow YH
PLoS One; 2013; 8(2):e57591. PubMed ID: 23451246
[TBL] [Abstract][Full Text] [Related]
4. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
Wu SC; Liu CC; Lian WC
Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
[TBL] [Abstract][Full Text] [Related]
5. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.
Chang JY; Chang CP; Tsai HH; Lee CD; Lian WC; Ih-Jen-Su ; Sai IH; Liu CC; Chou AH; Lu YJ; Chen CY; Lee PH; Chiang JR; Chong PC
Vaccine; 2012 Jan; 30(4):703-11. PubMed ID: 22142585
[TBL] [Abstract][Full Text] [Related]
6. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge.
Lin YL; Chow YH; Huang LM; Hsieh SM; Cheng PY; Hu KC; Chiang BL
Sci Rep; 2018 Jul; 8(1):10713. PubMed ID: 30013088
[TBL] [Abstract][Full Text] [Related]
7. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice.
Chang HW; Lin YW; Ho HM; Lin MH; Liu CC; Shao HY; Chong P; Sia C; Chow YH
PLoS One; 2013; 8(7):e69858. PubMed ID: 23936115
[TBL] [Abstract][Full Text] [Related]
8. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.
Chou AH; Liu CC; Chang CP; Guo MS; Hsieh SY; Yang WH; Chao HJ; Wu CL; Huang JL; Lee MS; Hu AY; Lin SC; Huang YY; Hu MH; Chow YH; Chiang JR; Chang JY; Chong P
PLoS One; 2012; 7(4):e34834. PubMed ID: 22529942
[TBL] [Abstract][Full Text] [Related]
9. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture.
Liu CC; Wu SC; Wu SR; Lin HY; Guo MS; Yung-Chih Hu A; Chow YH; Chiang JR; Shieh DB; Chong P
Vaccine; 2018 May; 36(22):3134-3139. PubMed ID: 28274636
[TBL] [Abstract][Full Text] [Related]
10. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.
Li J; Liu G; Liu X; Yang J; Chang J; Zhang W; Yu XF
Viruses; 2015 Jul; 7(7):3891-909. PubMed ID: 26193302
[TBL] [Abstract][Full Text] [Related]
11. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
13. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture.
Liu CC; Lian WC; Butler M; Wu SC
Vaccine; 2007 Jan; 25(1):19-24. PubMed ID: 16919374
[TBL] [Abstract][Full Text] [Related]
14. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
Hankaniemi MM; Laitinen OH; Stone VM; Sioofy-Khojine A; Määttä JAE; Larsson PG; Marjomäki V; Hyöty H; Flodström-Tullberg M; Hytönen VP
Vaccine; 2017 Jun; 35(30):3718-3725. PubMed ID: 28579231
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine.
Wang KT; Lin SJ; Wang HC; Chen PC; Lin JJ; Chiang JR; Chang CL; Shih DY; Lo CF; Wang DY
Biologicals; 2016 Jul; 44(4):183-190. PubMed ID: 27068365
[TBL] [Abstract][Full Text] [Related]
16. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system.
Liu CC; Guo MS; Lin FH; Hsiao KN; Chang KH; Chou AH; Wang YC; Chen YC; Yang CS; Chong PC
PLoS One; 2011; 6(5):e20005. PubMed ID: 21603631
[TBL] [Abstract][Full Text] [Related]
17. Development of a high-growth enterovirus 71 vaccine candidate inducing cross-reactive neutralizing antibody responses.
Chia MY; Chung WY; Wang CH; Chang WH; Lee MS
Vaccine; 2018 Feb; 36(9):1167-1173. PubMed ID: 29398272
[TBL] [Abstract][Full Text] [Related]
18. Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2.
Li X; Fan P; Jin J; Su W; An D; Xu L; Sun S; Zhang Y; Meng X; Gao F; Kong W; Jiang C
Virol J; 2013 Aug; 10():250. PubMed ID: 23919614
[TBL] [Abstract][Full Text] [Related]
19. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
Ku Z; Liu Q; Ye X; Cai Y; Wang X; Shi J; Li D; Jin X; An W; Huang Z
Vaccine; 2014 Jul; 32(34):4296-303. PubMed ID: 24950363
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
